Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra for cytokine storm syndrome secondary to severe COVID-19
2020-001825-29Phase 2Active
- Sponsor
- Navarrabiomed
- Start
- May 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of anakinra in coronavirus disease 2019 (COVID-19) and cytokine release syndrome (CRS), sponsored by Navarrabiomed. Primary endpoint: Treatment success (no mechanical ventilation by Day 15). Started May 2020; status: active.
02
Drugs
anakinra
03
Conditions
coronavirus disease 2019 (COVID-19)cytokine release syndrome (CRS)
Beyond the preview
Go deeper on 2020-001825-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001825-29.